Following the release of the Human Genome Sequence data in 2004, humans are considered to have 19,599 genes encoding proteins. Alternative RNA splicing and post-translational modification may result in 1 million or more proteins or protein fragments. As a consequence, the proteome is far more complex than the genome. Proteomics is the scientific discipline which studies proteins and searches for proteins that are associated with a disease by means of their altered levels of expression and/or post-translational modification between control and disease states. It enables correlations to be drawn between the range of proteins produced by a cell or tissue and the initiation or progression of a disease state and the effect of therapy. Proteome research permits the discovery of new protein markers for diagnostic purposes and of novel molecular targets for drug discovery. The abundance of information provided by proteome research is entirely complementary, with the genetic information being generated from genomics. Proteomics will make a key contribution to the development of functional genomics. The combination of proteomics and genomics will play a major role in biomedical research and will have a significant impact on the development of future generations of diagnostic and therapeutic products. Proteome Sciences, using its ProteoSHOP® technology platform, is ideally placed to accelerate the discovery of differential protein expression in disease and to exploit value from its application in functional genomics through strategic alliances and out-licensing.
Malcolm Ward joined Proteome Sciences in May 2001 having previously worked for GlaxoWellcome for 12 years, primarily undertaking analyses of proteins using mass spectrometry. He has helped to establish a new leading edge protein separation and mass spectrometry facility located within the Institute of Psychiatry, Kings College, London. Malcolm's research team is involved in a number of proteomics projects focused towards the discovery and development of new diagnostic tests and therapeutic agents to address several key human diseases. Malcolm has a first degree in Analytical Chemistry and is a member of the Royal Society of Chemistry. He also has a MSC in Molecular Biology and Immunology obtained from the University of Hertfordshire in 1996.
Dr. Jules Westbrook
Jules joined Proteome Sciences as a Separation Scientest in August 2001 and continues his Ph.D. studies. He has particular experience in 2-dimensional gel electrophoresis and image analysis and has helped introduce the use of narrow pH-range gels into Proteome Sciences through liaison with the academic proteomics group at Kings College London, led by Prof. Mike Dunn. Jules has developed considerable skills in image analysis, particularly with the Progenesis system, and was invited to present his experiences with this package at the recent 'PepTalk' meeting in San Diego, USA.
Dr. Ian Pike
Ian joined Proteome Sciences in November 2002 from Cancer Research Technology, the technology transfer and business development company owned by Cancer Research UK. Ian holds a Ph.D. in medical microbiology from the University of Leeds and ran a research group at Wellcome Diagnostics and subsequently Murex Biotech Ltd. for 8 years. In the four years after Murex he worked in academic technology transfer performing many licensing deals and working on the formation of three biotech start-ups. He has served as a non-executive director on the boards of Spirogen and Proacta Therapeutics, two biotechnology start-ups formed by Cancer Research Ventures. As Business Development Director at Proteome Sciences, Ian is responsible for the commercial development of its ProteoSHOP™ toolkit offering a combination of high-throughput and high sensitivity proteomics. Ian is also responsible for general licensing activities and management of the company's extensive intellectual property portfolio.